Search

Your search keyword '"Gwathmey, K."' showing total 29 results

Search Constraints

Start Over You searched for: Author "Gwathmey, K." Remove constraint Author: "Gwathmey, K."
29 results on '"Gwathmey, K."'

Search Results

1. D.1 Efficacy, safety, and tolerability of subcutaneous efgartigimod in chronic inflammatory demyelinating polyneuropathy: results from the ADHERE trial

2. PB1334 Safety Profile of Efgartigimod from Clinical Trials in Participants with Immunoglobulin G-Mediated Autoimmune Diseases

5. The Neuromuscular Fellowship Portal and Match

7. RASCH ANALYSIS OF THE IBMFRS: 7

9. Genome-wide Analyses Identify KIF5A as a Novel ALS Gene

10. Genome-wide Analyses Identify KIF5A as a Novel ALS Gene

11. P.045 Safety profile overview of Efgartigimod Clinical Trials in participants with diverse Diverse IgG-Mediated Autoimmune Diseases

12. Genome-wide Analyses Identify KIF5A as a Novel ALS Gene

13. Tubular aggregate myopathy causing progressive fatiguable weakness.

14. Racial disparities in ALS diagnostic delay: a single center's experience and review of potential contributing factors.

15. Multidisciplinary Clinics in Neuromuscular Medicine.

16. Primary lateral sclerosis natural history study - planning, designing, and early enrollment.

17. The natural history of ALS: Baseline characteristics from a multicenter clinical cohort.

18. Analysis of the spatial distribution of amyotrophic lateral sclerosis in Virginia.

19. Tackling Health Care Disparities: How to Build a Sarcoidosis Center.

20. Psychometric longitudinal evaluation of the Chronic Acquired Polyneuropathy Patient-Reported Index (CAPPRI) in patients with chronic inflammatory demyelinating polyneuropathy.

21. Anti-Neurofascin-Associated Nephrotic-Range Proteinuria in Chronic Inflammatory Demyelinating Polyneuropathy.

22. Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Its Variants.

23. Chronic Acquired Polyneuropathy Patient Reported Index (CAPPRI) in chronic inflammatory demyelinating polyradiculoneuropathy.

24. Investigation of the psychometric properties of the inclusion body myositis functional rating scale with rasch analysis.

25. Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine.

26. Disease course and therapeutic approach in dermatomyositis: A four-center retrospective study of 100 patients.

27. Neurologic indications for therapeutic plasma exchange: 2013 update.

28. Neurologic indications for therapeutic plasma exchange: 2011 update.

29. Neurologic indications for therapeutic plasma exchange: an update.

Catalog

Books, media, physical & digital resources